KYNTRA BIO, INC. — Form 8-K
Filed October 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Andrew E. Singer, MBA, appointed as independent director and Audit Committee member effective October 1, 2026, replacing Maykin Ho, Ph.D., who departed after eight years of service. Singer brings 25+ years of biotechnology finance and investment banking experience, including roles at Credit Suisse, Wells Fargo, and as CFO of Epizyme, with deal advisory experience exceeding $50 billion.
Why this rating
Routine board composition change. No financial impact, strategic value ambiguous for $21M company. Standard governance announcement.
See more from October 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.